ES2192585T3 - Superagonistas y antagonistas de la h il-6 y metodo de modelado tridimensional para su seleccion. - Google Patents
Superagonistas y antagonistas de la h il-6 y metodo de modelado tridimensional para su seleccion.Info
- Publication number
- ES2192585T3 ES2192585T3 ES95940409T ES95940409T ES2192585T3 ES 2192585 T3 ES2192585 T3 ES 2192585T3 ES 95940409 T ES95940409 T ES 95940409T ES 95940409 T ES95940409 T ES 95940409T ES 2192585 T3 ES2192585 T3 ES 2192585T3
- Authority
- ES
- Spain
- Prior art keywords
- interleucine
- superagonists
- antagonists
- superantagonists
- location
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5412—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/14—Lymphokine; related peptides
- Y10S930/141—Interleukin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Obesity (AREA)
Abstract
SE SABE QUE LOS LIGANDOS DEL GRUPO DE CITOQUINAS SIMILAR A LA INTERLEUCINA 6(IL-6), QUE ES ONCOSTATINA-M(OSM), EL FACTOR INHIBITORIO DE LA LEUCEMIA (LIF), EL FACTOR NEUROTROFICO CILIAR (CNTF) E LA INTERLEUCINA II (IL-II), INDUCEN LA FORMACION DE UN COMPLEJO RECEPTOR DEL CUAL FORMA PARTE LA MOLECULA DE MEMBRANA GP 130. LA PRESENTE INVENCION SE REFIERE A UNA METODOLOGIA PARA LA SELECCION DE SUPERAGONISTAS, ANTAGONISTAS Y SUPERANTAGONISTAS DE LA INTERLEUCINA-6 HUMANA QUE COMPRENDE LAS SIGUIENTES OPERACIONES: COMPARAR LA SECUENCIA DE AMINOACIDO DE LA COLONIA DE GRANULOCITOS BOVINOS QUE ESTIMULAN EL FACTOR (BG-CSF) CON LA SECUENCIA DE DICHA HORMONA, Y EN BASE A LA COMPARACION ANTERIORMENTE MENCIONADA, FORMULAR UN MODELO TRIDIMENSIONAL DE DICHA HORMONA, EL CUAL PERMITE LA IDENTIFICACION DE LOS RESIDUOS QUE FORMAN EL EMPLAZAMIENTO DE LA INTERACCION CON EL RECEPTOR ESPECIFICO (EMPLAZAMIENTO 1) Y ESOS QUE CONSTITUYEN EL EMPLAZAMIENTO DE LA INTERACCION CON EL GP 130 (EMPLAZAMIENTO 2) RESPECTIVAMENTE.LA INVENCION PERMITE LA IDENTIFICACION DE ESTOS EMPLAZAMIENTOS EN INTERLEUCINA-6 HUMANA Y EL AISLAMIENTO DE LAS VARIANTES QUE TIENEN, CON RESPECTO A LA HORMONA DE TIPO SALVAJE, UNA MAYOR AFINIDAD PARA EL RECEPTOR ESPECIFICO (SUPERAGONISTAS Y SUPERANTAGONISTAS) O AFINIDAD PARA EL GP 130 REDUCIDO O ABOLIDO (ANTAGONISTAS Y ANTAGONISTAS). LA FIGURA DEMUESTRA UN ESQUEMA QUE ILUSTRA LA METODOLOGIA APLICADA PARA IDENTIFICAR EL EMPLAZAMIENTO 1 Y EL EMPLAZAMIENTO 2 EN EL CASO DE LA INTERLEUCINA-6 HUMANA. LA INVENCION TAMBIEN DESCRIBE LA OBTENCION DE SUPERAGONISTAS Y SUPERANTAGONISTAS ESPECIFICAS DE LA INTERLEUCINA-6 Y EL USO DE SUPERANTAGONISTAS COMO INHIBIDORES DE DOSIS BAJA DEL CRECIMIENTO DE CELULAS DE MIELOMAS HUMANOS DEPENDIENTES DE LA INTERLEUCINA-6 DE TIPO SALAVAJE.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITRM940805A IT1274782B (it) | 1994-12-14 | 1994-12-14 | Metodo per selezionare superagonisti, antagonisti e superantagonisti di ormoni del cui complesso recettoriale fa parte gp 130 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2192585T3 true ES2192585T3 (es) | 2003-10-16 |
Family
ID=11402859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES95940409T Expired - Lifetime ES2192585T3 (es) | 1994-12-14 | 1995-12-13 | Superagonistas y antagonistas de la h il-6 y metodo de modelado tridimensional para su seleccion. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US5849283A (es) |
| EP (1) | EP0745094B1 (es) |
| JP (2) | JP3206919B2 (es) |
| CN (1) | CN1070866C (es) |
| AT (1) | ATE234864T1 (es) |
| AU (1) | AU702783B2 (es) |
| CA (1) | CA2177838A1 (es) |
| DE (1) | DE69529973T2 (es) |
| DK (1) | DK0745094T3 (es) |
| ES (1) | ES2192585T3 (es) |
| IT (1) | IT1274782B (es) |
| PT (1) | PT745094E (es) |
| WO (1) | WO1996018648A1 (es) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997016202A1 (en) * | 1995-10-27 | 1997-05-09 | Amrad Operations Pty. Ltd. | Cytokines and their use in treatment and/or prophylaxis of breast cancer |
| EP0869176A4 (en) * | 1995-11-07 | 2000-09-20 | Kaneka Corp | AUTOANTIGENS |
| IT1285790B1 (it) | 1996-09-24 | 1998-06-24 | Angeletti P Ist Richerche Bio | Adenovirus difettivi ricombinanti che codificano per mutanti di interleuchina 6 umana (hil-6) con attivita' antagonista o |
| AUPO439396A0 (en) * | 1996-12-24 | 1997-01-23 | Walter And Eliza Hall Institute Of Medical Research, The | A method of treatment and prophylaxis |
| GB9702944D0 (en) * | 1997-02-13 | 1997-04-02 | Univ Manchester | Reducing fibrosis |
| AU736282B2 (en) | 1997-03-21 | 2001-07-26 | Chugai Seiyaku Kabushiki Kaisha | A preventive or therapeutic agent for sensitized T cell- mediated diseases comprising IL-6 antagonist as an active ingredient |
| CA2237915A1 (en) | 1998-05-19 | 1999-11-19 | Stephen Shaughnessy | Osteoporosis treatment |
| AU753197B2 (en) | 1998-07-06 | 2002-10-10 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Compositions and methods for in vitro fertilization |
| CA2341239C (en) | 1998-08-24 | 2011-01-04 | Chugai Seiyaku Kabushiki Kaisha | A preventive or therapeutic agent for pancreatitis comprising il-6 antagonist as an active ingredient |
| JP4799516B2 (ja) * | 1998-08-24 | 2011-10-26 | 中外製薬株式会社 | Ｉｌ−６アンタゴニストを有効成分として含有する膵炎の予防又は治療剤 |
| US6541244B1 (en) * | 1999-06-07 | 2003-04-01 | Cedars-Sinai Medical Center | Suppressor of cytokine signaling (SOCS)-3 promoter and methods for its use in genetic therapy in humans |
| WO2001016166A2 (en) * | 1999-08-27 | 2001-03-08 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Polypeptides, comprising il-6 ligand-binding receptor domains, and related nucleic acids, antibodies, compositions, and methods of use |
| UA80091C2 (en) * | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
| US7247618B2 (en) * | 2001-04-30 | 2007-07-24 | Tripathi Rajavashisth | Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling |
| BRPI0214168B8 (pt) * | 2001-11-14 | 2021-05-25 | Centocor Inc | anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos |
| EP2002827A2 (en) | 2001-12-05 | 2008-12-17 | The Baylor College Of Medicine | Methods and compositions for control of bone formation via modulation of sympathetic tone |
| EP1607100A4 (en) | 2003-02-24 | 2007-06-13 | Chugai Pharmaceutical Co Ltd | MEDICAMENT WITH AN INTERLEUKIN-6 ANTAGONIST FOR BACK-MARGIN INJURIES |
| GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
| MXPA06003768A (es) | 2003-10-17 | 2006-06-23 | Chugai Pharmaceutical Co Ltd | Agente terapeutico para el mesotelioma. |
| US20050100550A1 (en) * | 2003-11-10 | 2005-05-12 | Mohit Trikha | Anti-angiogenic uses of IL-6 antagonists |
| AR048210A1 (es) | 2003-12-19 | 2006-04-12 | Chugai Pharmaceutical Co Ltd | Un agente preventivo para la vasculitis. |
| PA8672101A1 (es) | 2005-04-29 | 2006-12-07 | Centocor Inc | Anticuerpos anti-il-6, composiciones, métodos y usos |
| US8470316B2 (en) | 2005-10-14 | 2013-06-25 | Chugai Seiyaku Kabushiki Kaisha | Agents for suppressing damage to transplanted islets after islet transplantation |
| RU2450830C2 (ru) | 2005-10-21 | 2012-05-20 | Чугаи Сейяку Кабусики Кайся | Средства для лечения кардиопатии |
| AR057582A1 (es) | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | Agentes para suprimir la induccion de linfocitos t citotoxicos |
| WO2007061029A1 (ja) | 2005-11-25 | 2007-05-31 | Keio University | 前立腺癌治療剤 |
| JP5033643B2 (ja) | 2006-01-27 | 2012-09-26 | 学校法人慶應義塾 | 脈絡膜血管新生を伴う疾患の治療剤 |
| JP5754875B2 (ja) | 2006-04-07 | 2015-07-29 | 国立大学法人大阪大学 | 筋再生促進剤 |
| MX2009007830A (es) | 2007-01-23 | 2009-10-07 | Univ Shinshu | Inhibidor de rechazo cronico. |
| TW201503898A (zh) | 2008-06-05 | 2015-02-01 | Chugai Pharmaceutical Co Ltd | 神經浸潤抑制劑 |
| US8188235B2 (en) * | 2008-06-18 | 2012-05-29 | Pfizer Inc. | Antibodies to IL-6 and their uses |
| RS63800B1 (sr) | 2010-05-28 | 2022-12-30 | Chugai Pharmaceutical Co Ltd | Poboljšanje antitumorskog odgovora t ćelije |
| JP5904552B2 (ja) | 2010-05-28 | 2016-04-13 | 国立研究開発法人国立がん研究センター | 膵癌治療剤 |
| KR101933197B1 (ko) | 2010-11-08 | 2018-12-27 | 제넨테크, 인크. | 피하 투여용 항―ｉｌ―6 수용체 항체 |
| EP3009518B1 (en) | 2013-06-11 | 2020-08-12 | National Center of Neurology and Psychiatry | Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy |
| EP2898896A1 (en) | 2014-01-22 | 2015-07-29 | Université Pierre et Marie Curie (Paris 6) | Agents for use in the treatment of retinal inflammation |
| TWI759261B (zh) | 2015-02-27 | 2022-04-01 | 日商中外製藥股份有限公司 | Ｉｌ－６受體抗體用於製備醫藥組成物的用途 |
| US20190060286A1 (en) | 2016-02-29 | 2019-02-28 | University Of Florida Research Foundation, Incorpo | Chemotherapeutic Methods |
| EP3620531A4 (en) | 2017-05-02 | 2021-03-17 | National Center of Neurology and Psychiatry | METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS |
| TWI822728B (zh) | 2018-01-31 | 2023-11-21 | 加藤元一 | 含有il-6抑制劑的哮喘治療劑 |
| AU2020259884A1 (en) | 2019-04-17 | 2021-10-07 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination |
| CN118566192B (zh) * | 2024-06-18 | 2026-06-23 | 复旦大学 | 基于相转变结合FRET的FcRn小分子拮抗剂筛选的方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU687763B2 (en) * | 1992-10-20 | 1998-03-05 | Central Laboratory Of The Netherlands Red Cross Blood Transfusion Service | Interleukin-6 receptor antagonists |
| IT1263022B (it) * | 1992-11-06 | 1996-07-23 | Angeletti P Ist Richerche Bio | Interleuchina-6 mutante con attivita' biologica migliorata rispetto all'interleuchina-6 selvatica. |
-
1994
- 1994-12-14 IT ITRM940805A patent/IT1274782B/it active IP Right Grant
-
1995
- 1995-12-13 US US08/693,182 patent/US5849283A/en not_active Expired - Fee Related
- 1995-12-13 AU AU41871/96A patent/AU702783B2/en not_active Ceased
- 1995-12-13 AT AT95940409T patent/ATE234864T1/de not_active IP Right Cessation
- 1995-12-13 CA CA002177838A patent/CA2177838A1/en not_active Abandoned
- 1995-12-13 DE DE69529973T patent/DE69529973T2/de not_active Expired - Fee Related
- 1995-12-13 EP EP95940409A patent/EP0745094B1/en not_active Expired - Lifetime
- 1995-12-13 WO PCT/IT1995/000216 patent/WO1996018648A1/en not_active Ceased
- 1995-12-13 CN CN95191575A patent/CN1070866C/zh not_active Expired - Fee Related
- 1995-12-13 DK DK95940409T patent/DK0745094T3/da active
- 1995-12-13 ES ES95940409T patent/ES2192585T3/es not_active Expired - Lifetime
- 1995-12-13 JP JP51856296A patent/JP3206919B2/ja not_active Expired - Fee Related
- 1995-12-13 PT PT95940409T patent/PT745094E/pt unknown
-
1998
- 1998-01-16 US US09/008,482 patent/US5914106A/en not_active Expired - Fee Related
-
2001
- 2001-04-24 JP JP2001125516A patent/JP3286310B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2001354698A (ja) | 2001-12-25 |
| IT1274782B (it) | 1997-07-24 |
| EP0745094A1 (en) | 1996-12-04 |
| JPH09502460A (ja) | 1997-03-11 |
| JP3206919B2 (ja) | 2001-09-10 |
| ITRM940805A1 (it) | 1996-06-14 |
| CN1070866C (zh) | 2001-09-12 |
| PT745094E (pt) | 2003-07-31 |
| US5914106A (en) | 1999-06-22 |
| AU4187196A (en) | 1996-07-03 |
| EP0745094B1 (en) | 2003-03-19 |
| WO1996018648A1 (en) | 1996-06-20 |
| HK1011032A1 (en) | 1999-07-02 |
| ITRM940805A0 (it) | 1994-12-14 |
| DK0745094T3 (da) | 2003-06-10 |
| DE69529973D1 (de) | 2003-04-24 |
| ATE234864T1 (de) | 2003-04-15 |
| JP3286310B2 (ja) | 2002-05-27 |
| AU702783B2 (en) | 1999-03-04 |
| CA2177838A1 (en) | 1996-06-15 |
| CN1140456A (zh) | 1997-01-15 |
| DE69529973T2 (de) | 2003-12-04 |
| US5849283A (en) | 1998-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT745094E (pt) | Superagonistas e antagonistas da il-6 humana e metodo para a sua seleccao | |
| ES2177789T3 (es) | Peptidos antagonistas de lhrh. | |
| DE69233772D1 (de) | T-zell epitopen von den wichtigsten allergene von dermatophagoides (hausmilbe) | |
| ES2056908T3 (es) | Analogos nonapeptidos y decapeptidos de la lhrh utiles como antagonistas de la lhrh. | |
| CY1107556T1 (el) | Συνθεσεις αναλογων g-csf και μεθοδοι | |
| EP1680443A4 (en) | PEPTIDES WITH STABILIZED ALPHA HELIX AND ITS USES | |
| ES2170172T3 (es) | Procedimiento y composiciones para inhibir las proteina quinasas. | |
| DK149896C (da) | Analogifremgangsmaade til fremstilling af lrf-analoge nona- eller decapeptidamider eller ikke-toksiske salte deraf | |
| ES535842A0 (es) | Un procedimiento para preparar octapeptidos lineales | |
| ES2059354T3 (es) | Un metodo para producir un polipeptido. | |
| MX9604047A (es) | Secrecion aumentada de polipeptidos. | |
| ATE306549T1 (de) | C-c ckr-1, ein c-c chemokin rezeptor | |
| MX9203519A (es) | Metodo de recombinacion para la produccion de inhibidores de proteasa de serina y secuencias de adn utiles para los mismos. | |
| YU46223B (sh) | Postupak za dobivanje 1-/4-aminofenil/-4-metil-7,8-metilendioksi-3,4-dihid ro-5h-2,3-benzodiazepina | |
| BG104267A (en) | Aminoterminally incised rantes as haemokin antagonists | |
| NO165804C (no) | Veksthormon-frigjoerende peptider og anvendelse derav. | |
| ES2090018T3 (es) | Clon de adn de trombomodulina humana. | |
| SE8403630L (sv) | Humana proteiner | |
| ES2144524T3 (es) | Metodologia para seleccionar superagonistas, antagonistas y superantagonistas de la interleuquina 6. | |
| ES519855A0 (es) | Un procedimiento para la preparacion de 1-(3-halo-2-piridinil) piperazinas. | |
| ES2000170A6 (es) | Procedimiento para preparar 5,11-dihidro-6h-pirido(2,3-b)(1,4)-benzodiazepin-6-onas substituidas en posicion 11 | |
| FI811682L (fi) | Lh-rh antagonister | |
| Clottes | European Palaeolithic rock art and spatial structures | |
| ES2084627T3 (es) | Antagonistas de neuroquinina ciclica. | |
| DD128973A1 (de) | Verfahren zur herstellung von peptiden,die tyrosinsulfat enthalten |